ADDITIONAL RESOURCES: Video, hard copy requests, contact information and more available at: http://www.prnewswire.com/broadcast/26505/consumer.html THIS IS A MULTIVU SPECIAL REPORT BROUGHT TO YOU BY SCHERING-PLOUGH CORPORATION. EACH YEAR IN THE UNITED STATES MORE THAN 1.3 MILLION HOSPITAL PATIENTS ARE AFFECTED BY INVASIVE FUNGAL INFECTIONS OR IFIS. ONCE IFIS ARE ESTABLISHED IN HIGH-RISK PATIENTS, SUCH AS STEM CELL TRANSPLANT RECIPIENTS OR NEUTROPENIC CHEMOTHERAPY PATIENTS, THEY ARE EXTREMELY DIFFICULT TO TREAT, WITH MORTALITY RATES RANGING FROM 50 TO 90 PERCENT. ACCORDING TO TWO LANDMARK STUDIES PUBLISHED RECENTLY IN THE NEW ENGLAND JOURNAL OF MEDICINE, NOXAFIL - A POTENT NEW AGENT TO PREVENT IFIS -- SIGNIFICANTLY REDUCED THE NUMBER OF DEATHS DUE TO FUNGAL INFECTIONS COMPARED TO OTHER ANTIFUNGALS. ANDREW J. ULLMANN, M.D., LEAD AUTHOR OF ONE OF THE PUBLISHED STUDIES: "These studies demonstrate that posaconazole prophylaxis provides effective, well-tolerated, preventive therapy, allowing physicians to focus on treating their patient's underlying disease." NOXAFIL IS THE FIRST AND ONLY ANTIFUNGAL AGENT APPROVED TO PREVENT THE TWO MOST COMMON TYPES OF IFIS. FOR MORE INFORMATION, VISIT, SCHERING-PLOUGH.COM. I'M CHRISTIANE ARBESU. AUDIO PROVIDED BY: Schering-Plough Corporation http://www.prnewswire.com/broadcast/26505/consumer.htmlDATASOURCE: Schering-Plough Corporation CONTACT: FOR STORY INFORMATION, PLEASE CALL: MultiVu Media Relations, 1-800-653-5313, EXT. 3 OR EMAIL Web site: http://www.schering-plough.com/

Copyright